vs
Side-by-side financial comparison of Allot Ltd. (ALLT) and Autolus Therapeutics plc (AUTL). Click either name above to swap in a different company.
Allot Ltd. is the larger business by last-quarter revenue ($24.1M vs $21.2M, roughly 1.1× Autolus Therapeutics plc). Allot Ltd. runs the higher net margin — -7.0% vs -373.3%, a 366.3% gap on every dollar of revenue. Allot Ltd. produced more free cash flow last quarter ($4.0M vs $-72.3M).
Allot Ltd., formerly Allot Communications, is an Israeli high-tech company that develops telecommunications software. The company is headquartered in Hod Hasharon, Israel.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
ALLT vs AUTL — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $24.1M | $21.2M |
| Net Profit | $-1.7M | $-79.1M |
| Gross Margin | 72.1% | — |
| Operating Margin | -1.7% | -337.9% |
| Net Margin | -7.0% | -373.3% |
| Revenue YoY | 8.5% | — |
| Net Profit YoY | 49.6% | 3.6% |
| EPS (diluted) | $-0.04 | $-0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $21.2M | ||
| Q2 25 | $24.1M | $20.9M | ||
| Q1 25 | $23.1M | $9.0M | ||
| Q3 24 | — | $0 | ||
| Q2 24 | $22.2M | $0 | ||
| Q1 24 | — | $10.1M | ||
| Q2 23 | $25.0M | — | ||
| Q2 22 | $32.8M | — |
| Q3 25 | — | $-79.1M | ||
| Q2 25 | $-1.7M | $-47.9M | ||
| Q1 25 | $-332.0K | $-70.2M | ||
| Q3 24 | — | $-82.1M | ||
| Q2 24 | $-3.4M | $-58.3M | ||
| Q1 24 | — | $-52.7M | ||
| Q2 23 | $-20.7M | — | ||
| Q2 22 | $-6.2M | — |
| Q3 25 | — | — | ||
| Q2 25 | 72.1% | — | ||
| Q1 25 | 69.3% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 68.5% | — | ||
| Q1 24 | — | — | ||
| Q2 23 | 69.2% | — | ||
| Q2 22 | 68.7% | — |
| Q3 25 | — | -337.9% | ||
| Q2 25 | -1.7% | -292.6% | ||
| Q1 25 | -3.1% | -726.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | -15.2% | — | ||
| Q1 24 | — | -384.1% | ||
| Q2 23 | -85.8% | — | ||
| Q2 22 | -19.8% | — |
| Q3 25 | — | -373.3% | ||
| Q2 25 | -7.0% | -229.0% | ||
| Q1 25 | -1.4% | -781.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | -15.1% | — | ||
| Q1 24 | — | -522.1% | ||
| Q2 23 | -82.8% | — | ||
| Q2 22 | -19.0% | — |
| Q3 25 | — | $-0.30 | ||
| Q2 25 | $-0.04 | $-0.18 | ||
| Q1 25 | $-0.01 | $-0.26 | ||
| Q3 24 | — | $-0.31 | ||
| Q2 24 | $-0.09 | $-0.22 | ||
| Q1 24 | — | $-0.24 | ||
| Q2 23 | $-0.55 | — | ||
| Q2 22 | $-0.17 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.1M | $86.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $99.7M | $265.5M |
| Total Assets | $154.1M | $661.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $86.1M | ||
| Q2 25 | $60.1M | $123.8M | ||
| Q1 25 | $10.1M | $95.8M | ||
| Q3 24 | — | $657.1M | ||
| Q2 24 | $15.9M | $705.9M | ||
| Q1 24 | — | $758.5M | ||
| Q2 23 | $15.5M | — | ||
| Q2 22 | $15.5M | — |
| Q3 25 | — | $265.5M | ||
| Q2 25 | $99.7M | $346.5M | ||
| Q1 25 | $50.0M | $371.1M | ||
| Q3 24 | — | $477.0M | ||
| Q2 24 | $46.7M | $527.8M | ||
| Q1 24 | — | $582.0M | ||
| Q2 23 | $76.1M | — | ||
| Q2 22 | $114.4M | — |
| Q3 25 | — | $661.9M | ||
| Q2 25 | $154.1M | $721.0M | ||
| Q1 25 | $140.3M | $746.3M | ||
| Q3 24 | — | $827.5M | ||
| Q2 24 | $132.5M | $853.6M | ||
| Q1 24 | — | $901.4M | ||
| Q2 23 | $177.8M | — | ||
| Q2 22 | $229.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.4M | $-67.9M |
| Free Cash FlowOCF − Capex | $4.0M | $-72.3M |
| FCF MarginFCF / Revenue | 16.5% | -341.2% |
| Capex IntensityCapex / Revenue | 1.7% | 20.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-6.0M | $-322.5M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-67.9M | ||
| Q2 25 | $4.4M | $-72.8M | ||
| Q1 25 | $1.7M | $-75.6M | ||
| Q3 24 | — | $-76.7M | ||
| Q2 24 | $1.2M | $-51.1M | ||
| Q1 24 | — | $-40.5M | ||
| Q2 23 | $-11.3M | — | ||
| Q2 22 | $-7.8M | — |
| Q3 25 | — | $-72.3M | ||
| Q2 25 | $4.0M | $-80.1M | ||
| Q1 25 | $1.4M | $-83.8M | ||
| Q3 24 | — | $-86.3M | ||
| Q2 24 | $217.0K | $-51.9M | ||
| Q1 24 | — | $-41.0M | ||
| Q2 23 | $-11.6M | — | ||
| Q2 22 | $-9.1M | — |
| Q3 25 | — | -341.2% | ||
| Q2 25 | 16.5% | -382.6% | ||
| Q1 25 | 6.1% | -933.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | — | -406.8% | ||
| Q2 23 | -46.4% | — | ||
| Q2 22 | -27.7% | — |
| Q3 25 | — | 20.8% | ||
| Q2 25 | 1.7% | 34.8% | ||
| Q1 25 | 1.2% | 91.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | 4.3% | — | ||
| Q1 24 | — | 5.3% | ||
| Q2 23 | 1.2% | — | ||
| Q2 22 | 3.9% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
